nodes	percent_of_prediction	percent_of_DWPC	metapath
Auranofin—ALB—Abiraterone—prostate cancer	0.168	0.401	CbGbCtD
Auranofin—ALB—Estrone—prostate cancer	0.121	0.29	CbGbCtD
Auranofin—ALB—Estradiol—prostate cancer	0.0696	0.166	CbGbCtD
Auranofin—ALB—Prednisone—prostate cancer	0.0599	0.143	CbGbCtD
Auranofin—PRDX5—prostate gland—prostate cancer	0.0121	0.145	CbGeAlD
Auranofin—PRDX5—seminal vesicle—prostate cancer	0.0102	0.122	CbGeAlD
Auranofin—PRDX5—epithelium—prostate cancer	0.0089	0.106	CbGeAlD
Auranofin—PRDX5—renal system—prostate cancer	0.00825	0.0987	CbGeAlD
Auranofin—PRDX5—urethra—prostate cancer	0.00811	0.0969	CbGeAlD
Auranofin—IKBKB—prostate gland—prostate cancer	0.00717	0.0857	CbGeAlD
Auranofin—PRDX5—bone marrow—prostate cancer	0.00624	0.0746	CbGeAlD
Auranofin—PRDX5—testis—prostate cancer	0.00533	0.0638	CbGeAlD
Auranofin—IKBKB—urethra—prostate cancer	0.0048	0.0574	CbGeAlD
Auranofin—PRDX5—lymph node—prostate cancer	0.00387	0.0462	CbGeAlD
Auranofin—IKBKB—testis—prostate cancer	0.00316	0.0378	CbGeAlD
Auranofin—IKBKB—lymph node—prostate cancer	0.00229	0.0274	CbGeAlD
Auranofin—ALB—testis—prostate cancer	0.00184	0.022	CbGeAlD
Auranofin—ALB—lymph node—prostate cancer	0.00134	0.016	CbGeAlD
Auranofin—Nausea—Cabazitaxel—prostate cancer	0.000432	0.00186	CcSEcCtD
Auranofin—Gastrointestinal pain—Ethinyl Estradiol—prostate cancer	0.000431	0.00186	CcSEcCtD
Auranofin—Alopecia—Estradiol—prostate cancer	0.000428	0.00184	CcSEcCtD
Auranofin—Diarrhoea—Bicalutamide—prostate cancer	0.000427	0.00184	CcSEcCtD
Auranofin—Thrombocytopenia—Goserelin—prostate cancer	0.000425	0.00183	CcSEcCtD
Auranofin—Glossitis—Doxorubicin—prostate cancer	0.000421	0.00181	CcSEcCtD
Auranofin—Urticaria—Ethinyl Estradiol—prostate cancer	0.000419	0.00181	CcSEcCtD
Auranofin—Abdominal pain—Ethinyl Estradiol—prostate cancer	0.000417	0.0018	CcSEcCtD
Auranofin—Flatulence—Estradiol—prostate cancer	0.000415	0.00179	CcSEcCtD
Auranofin—Anorexia—Goserelin—prostate cancer	0.000414	0.00178	CcSEcCtD
Auranofin—Dysgeusia—Estradiol—prostate cancer	0.000413	0.00178	CcSEcCtD
Auranofin—Neuropathy peripheral—Etoposide—prostate cancer	0.00041	0.00177	CcSEcCtD
Auranofin—Anorexia—Conjugated Estrogens—prostate cancer	0.00041	0.00177	CcSEcCtD
Auranofin—Melaena—Epirubicin—prostate cancer	0.000409	0.00176	CcSEcCtD
Auranofin—Jaundice—Etoposide—prostate cancer	0.000408	0.00176	CcSEcCtD
Auranofin—Stomatitis—Etoposide—prostate cancer	0.000408	0.00176	CcSEcCtD
Auranofin—Alopecia—Mitoxantrone—prostate cancer	0.000399	0.00172	CcSEcCtD
Auranofin—Vomiting—Bicalutamide—prostate cancer	0.000397	0.00171	CcSEcCtD
Auranofin—Rash—Bicalutamide—prostate cancer	0.000393	0.0017	CcSEcCtD
Auranofin—Aplastic anaemia—Epirubicin—prostate cancer	0.000393	0.0017	CcSEcCtD
Auranofin—Dermatitis—Bicalutamide—prostate cancer	0.000393	0.00169	CcSEcCtD
Auranofin—Agranulocytosis—Etoposide—prostate cancer	0.00039	0.00168	CcSEcCtD
Auranofin—Dysphagia—Docetaxel—prostate cancer	0.00039	0.00168	CcSEcCtD
Auranofin—Gastrointestinal haemorrhage—Prednisone—prostate cancer	0.000389	0.00168	CcSEcCtD
Auranofin—Angioedema—Estradiol—prostate cancer	0.000385	0.00166	CcSEcCtD
Auranofin—Dysgeusia—Mitoxantrone—prostate cancer	0.000385	0.00166	CcSEcCtD
Auranofin—Dyspepsia—Goserelin—prostate cancer	0.000382	0.00165	CcSEcCtD
Auranofin—Melaena—Doxorubicin—prostate cancer	0.000379	0.00163	CcSEcCtD
Auranofin—Dyspepsia—Conjugated Estrogens—prostate cancer	0.000378	0.00163	CcSEcCtD
Auranofin—Dysphagia—Capecitabine—prostate cancer	0.000377	0.00163	CcSEcCtD
Auranofin—Decreased appetite—Goserelin—prostate cancer	0.000377	0.00163	CcSEcCtD
Auranofin—Decreased appetite—Conjugated Estrogens—prostate cancer	0.000374	0.00161	CcSEcCtD
Auranofin—Pruritus—Ethinyl Estradiol—prostate cancer	0.000373	0.00161	CcSEcCtD
Auranofin—Constipation—Goserelin—prostate cancer	0.000371	0.0016	CcSEcCtD
Auranofin—Nausea—Bicalutamide—prostate cancer	0.000371	0.0016	CcSEcCtD
Auranofin—Pancytopenia—Docetaxel—prostate cancer	0.00037	0.0016	CcSEcCtD
Auranofin—Constipation—Conjugated Estrogens—prostate cancer	0.000368	0.00158	CcSEcCtD
Auranofin—Neutropenia—Docetaxel—prostate cancer	0.000364	0.00157	CcSEcCtD
Auranofin—Aplastic anaemia—Doxorubicin—prostate cancer	0.000364	0.00157	CcSEcCtD
Auranofin—Anaemia—Mitoxantrone—prostate cancer	0.000363	0.00156	CcSEcCtD
Auranofin—Diarrhoea—Ethinyl Estradiol—prostate cancer	0.000361	0.00156	CcSEcCtD
Auranofin—Pancytopenia—Capecitabine—prostate cancer	0.000358	0.00154	CcSEcCtD
Auranofin—Gastrointestinal pain—Goserelin—prostate cancer	0.000355	0.00153	CcSEcCtD
Auranofin—Neutropenia—Capecitabine—prostate cancer	0.000353	0.00152	CcSEcCtD
Auranofin—Weight decreased—Docetaxel—prostate cancer	0.000353	0.00152	CcSEcCtD
Auranofin—Leukopenia—Mitoxantrone—prostate cancer	0.000352	0.00152	CcSEcCtD
Auranofin—Gastrointestinal pain—Conjugated Estrogens—prostate cancer	0.000352	0.00152	CcSEcCtD
Auranofin—Eye disorder—Etoposide—prostate cancer	0.000351	0.00151	CcSEcCtD
Auranofin—Urticaria—Goserelin—prostate cancer	0.000345	0.00149	CcSEcCtD
Auranofin—Abdominal pain—Goserelin—prostate cancer	0.000343	0.00148	CcSEcCtD
Auranofin—Urticaria—Conjugated Estrogens—prostate cancer	0.000342	0.00147	CcSEcCtD
Auranofin—Weight decreased—Capecitabine—prostate cancer	0.000341	0.00147	CcSEcCtD
Auranofin—Neuropathy peripheral—Docetaxel—prostate cancer	0.000341	0.00147	CcSEcCtD
Auranofin—Abdominal pain—Conjugated Estrogens—prostate cancer	0.00034	0.00146	CcSEcCtD
Auranofin—Jaundice—Docetaxel—prostate cancer	0.000339	0.00146	CcSEcCtD
Auranofin—Stomatitis—Docetaxel—prostate cancer	0.000339	0.00146	CcSEcCtD
Auranofin—Conjunctivitis—Docetaxel—prostate cancer	0.000338	0.00146	CcSEcCtD
Auranofin—Vomiting—Ethinyl Estradiol—prostate cancer	0.000335	0.00145	CcSEcCtD
Auranofin—Rash—Ethinyl Estradiol—prostate cancer	0.000333	0.00143	CcSEcCtD
Auranofin—Dermatitis—Ethinyl Estradiol—prostate cancer	0.000332	0.00143	CcSEcCtD
Auranofin—Alopecia—Etoposide—prostate cancer	0.000332	0.00143	CcSEcCtD
Auranofin—Neuropathy peripheral—Capecitabine—prostate cancer	0.00033	0.00142	CcSEcCtD
Auranofin—Stomatitis—Capecitabine—prostate cancer	0.000328	0.00141	CcSEcCtD
Auranofin—Jaundice—Capecitabine—prostate cancer	0.000328	0.00141	CcSEcCtD
Auranofin—Conjunctivitis—Capecitabine—prostate cancer	0.000327	0.00141	CcSEcCtD
Auranofin—Agranulocytosis—Docetaxel—prostate cancer	0.000324	0.0014	CcSEcCtD
Auranofin—Dermatitis exfoliative—Epirubicin—prostate cancer	0.000322	0.00139	CcSEcCtD
Auranofin—Haematuria—Capecitabine—prostate cancer	0.000321	0.00138	CcSEcCtD
Auranofin—Dysgeusia—Etoposide—prostate cancer	0.00032	0.00138	CcSEcCtD
Auranofin—Neutropenia—Prednisone—prostate cancer	0.000314	0.00135	CcSEcCtD
Auranofin—Agranulocytosis—Capecitabine—prostate cancer	0.000314	0.00135	CcSEcCtD
Auranofin—Thrombocytopenia—Mitoxantrone—prostate cancer	0.000314	0.00135	CcSEcCtD
Auranofin—Nausea—Ethinyl Estradiol—prostate cancer	0.000313	0.00135	CcSEcCtD
Auranofin—Pruritus—Goserelin—prostate cancer	0.000307	0.00132	CcSEcCtD
Auranofin—Anorexia—Mitoxantrone—prostate cancer	0.000306	0.00132	CcSEcCtD
Auranofin—Pruritus—Conjugated Estrogens—prostate cancer	0.000304	0.00131	CcSEcCtD
Auranofin—Gastrointestinal haemorrhage—Epirubicin—prostate cancer	0.000304	0.00131	CcSEcCtD
Auranofin—Weight decreased—Prednisone—prostate cancer	0.000304	0.00131	CcSEcCtD
Auranofin—Dyspepsia—Estradiol—prostate cancer	0.000303	0.00131	CcSEcCtD
Auranofin—Anaemia—Etoposide—prostate cancer	0.000302	0.0013	CcSEcCtD
Auranofin—Visual impairment—Docetaxel—prostate cancer	0.000301	0.0013	CcSEcCtD
Auranofin—Decreased appetite—Estradiol—prostate cancer	0.000299	0.00129	CcSEcCtD
Auranofin—Dermatitis exfoliative—Doxorubicin—prostate cancer	0.000298	0.00129	CcSEcCtD
Auranofin—Diarrhoea—Goserelin—prostate cancer	0.000297	0.00128	CcSEcCtD
Auranofin—Constipation—Estradiol—prostate cancer	0.000294	0.00127	CcSEcCtD
Auranofin—Diarrhoea—Conjugated Estrogens—prostate cancer	0.000294	0.00127	CcSEcCtD
Auranofin—Neuropathy peripheral—Prednisone—prostate cancer	0.000294	0.00127	CcSEcCtD
Auranofin—Leukopenia—Etoposide—prostate cancer	0.000293	0.00126	CcSEcCtD
Auranofin—Eye disorder—Docetaxel—prostate cancer	0.000292	0.00126	CcSEcCtD
Auranofin—Visual impairment—Capecitabine—prostate cancer	0.000291	0.00125	CcSEcCtD
Auranofin—Eye disorder—Capecitabine—prostate cancer	0.000282	0.00122	CcSEcCtD
Auranofin—Dyspepsia—Mitoxantrone—prostate cancer	0.000282	0.00122	CcSEcCtD
Auranofin—Gastrointestinal haemorrhage—Doxorubicin—prostate cancer	0.000281	0.00121	CcSEcCtD
Auranofin—Gastrointestinal pain—Estradiol—prostate cancer	0.000281	0.00121	CcSEcCtD
Auranofin—Decreased appetite—Mitoxantrone—prostate cancer	0.000279	0.0012	CcSEcCtD
Auranofin—Vomiting—Goserelin—prostate cancer	0.000276	0.00119	CcSEcCtD
Auranofin—Alopecia—Docetaxel—prostate cancer	0.000276	0.00119	CcSEcCtD
Auranofin—Constipation—Mitoxantrone—prostate cancer	0.000274	0.00118	CcSEcCtD
Auranofin—Rash—Goserelin—prostate cancer	0.000274	0.00118	CcSEcCtD
Auranofin—Dermatitis—Goserelin—prostate cancer	0.000273	0.00118	CcSEcCtD
Auranofin—Vomiting—Conjugated Estrogens—prostate cancer	0.000273	0.00118	CcSEcCtD
Auranofin—Urticaria—Estradiol—prostate cancer	0.000273	0.00118	CcSEcCtD
Auranofin—Abdominal pain—Estradiol—prostate cancer	0.000272	0.00117	CcSEcCtD
Auranofin—Rash—Conjugated Estrogens—prostate cancer	0.000271	0.00117	CcSEcCtD
Auranofin—Dermatitis—Conjugated Estrogens—prostate cancer	0.000271	0.00117	CcSEcCtD
Auranofin—Alopecia—Capecitabine—prostate cancer	0.000267	0.00115	CcSEcCtD
Auranofin—Dysgeusia—Docetaxel—prostate cancer	0.000266	0.00115	CcSEcCtD
Auranofin—Dysphagia—Epirubicin—prostate cancer	0.000263	0.00113	CcSEcCtD
Auranofin—Gastrointestinal pain—Mitoxantrone—prostate cancer	0.000262	0.00113	CcSEcCtD
Auranofin—Thrombocytopenia—Etoposide—prostate cancer	0.000261	0.00113	CcSEcCtD
Auranofin—Eosinophilia—Epirubicin—prostate cancer	0.00026	0.00112	CcSEcCtD
Auranofin—Flatulence—Capecitabine—prostate cancer	0.000259	0.00112	CcSEcCtD
Auranofin—Nausea—Goserelin—prostate cancer	0.000258	0.00111	CcSEcCtD
Auranofin—Dysgeusia—Capecitabine—prostate cancer	0.000257	0.00111	CcSEcCtD
Auranofin—Nausea—Conjugated Estrogens—prostate cancer	0.000255	0.0011	CcSEcCtD
Auranofin—Urticaria—Mitoxantrone—prostate cancer	0.000255	0.0011	CcSEcCtD
Auranofin—Anorexia—Etoposide—prostate cancer	0.000254	0.0011	CcSEcCtD
Auranofin—Abdominal pain—Mitoxantrone—prostate cancer	0.000253	0.00109	CcSEcCtD
Auranofin—Eye disorder—Prednisone—prostate cancer	0.000251	0.00108	CcSEcCtD
Auranofin—Anaemia—Docetaxel—prostate cancer	0.000251	0.00108	CcSEcCtD
Auranofin—Pancytopenia—Epirubicin—prostate cancer	0.00025	0.00108	CcSEcCtD
Auranofin—Neutropenia—Epirubicin—prostate cancer	0.000246	0.00106	CcSEcCtD
Auranofin—Pruritus—Estradiol—prostate cancer	0.000243	0.00105	CcSEcCtD
Auranofin—Dysphagia—Doxorubicin—prostate cancer	0.000243	0.00105	CcSEcCtD
Auranofin—Leukopenia—Docetaxel—prostate cancer	0.000243	0.00105	CcSEcCtD
Auranofin—Anaemia—Capecitabine—prostate cancer	0.000243	0.00105	CcSEcCtD
Auranofin—Eosinophilia—Doxorubicin—prostate cancer	0.000241	0.00104	CcSEcCtD
Auranofin—Weight decreased—Epirubicin—prostate cancer	0.000238	0.00102	CcSEcCtD
Auranofin—Alopecia—Prednisone—prostate cancer	0.000238	0.00102	CcSEcCtD
Auranofin—Diarrhoea—Estradiol—prostate cancer	0.000235	0.00101	CcSEcCtD
Auranofin—Leukopenia—Capecitabine—prostate cancer	0.000235	0.00101	CcSEcCtD
Auranofin—Decreased appetite—Etoposide—prostate cancer	0.000232	0.000999	CcSEcCtD
Auranofin—Pancytopenia—Doxorubicin—prostate cancer	0.000231	0.000995	CcSEcCtD
Auranofin—Neuropathy peripheral—Epirubicin—prostate cancer	0.00023	0.00099	CcSEcCtD
Auranofin—Stomatitis—Epirubicin—prostate cancer	0.000228	0.000985	CcSEcCtD
Auranofin—Jaundice—Epirubicin—prostate cancer	0.000228	0.000985	CcSEcCtD
Auranofin—Constipation—Etoposide—prostate cancer	0.000228	0.000983	CcSEcCtD
Auranofin—Conjunctivitis—Epirubicin—prostate cancer	0.000228	0.000982	CcSEcCtD
Auranofin—Neutropenia—Doxorubicin—prostate cancer	0.000227	0.00098	CcSEcCtD
Auranofin—Haematuria—Epirubicin—prostate cancer	0.000223	0.000963	CcSEcCtD
Auranofin—Weight decreased—Doxorubicin—prostate cancer	0.00022	0.000948	CcSEcCtD
Auranofin—Diarrhoea—Mitoxantrone—prostate cancer	0.000219	0.000945	CcSEcCtD
Auranofin—Vomiting—Estradiol—prostate cancer	0.000219	0.000943	CcSEcCtD
Auranofin—Agranulocytosis—Epirubicin—prostate cancer	0.000219	0.000943	CcSEcCtD
Auranofin—Gastrointestinal pain—Etoposide—prostate cancer	0.000218	0.00094	CcSEcCtD
Auranofin—Thrombocytopenia—Docetaxel—prostate cancer	0.000217	0.000935	CcSEcCtD
Auranofin—Rash—Estradiol—prostate cancer	0.000217	0.000935	CcSEcCtD
Auranofin—Dermatitis—Estradiol—prostate cancer	0.000217	0.000934	CcSEcCtD
Auranofin—Anaemia—Prednisone—prostate cancer	0.000216	0.000933	CcSEcCtD
Auranofin—Angioedema—Prednisone—prostate cancer	0.000214	0.000922	CcSEcCtD
Auranofin—Neuropathy peripheral—Doxorubicin—prostate cancer	0.000213	0.000916	CcSEcCtD
Auranofin—Urticaria—Etoposide—prostate cancer	0.000212	0.000913	CcSEcCtD
Auranofin—Jaundice—Doxorubicin—prostate cancer	0.000211	0.000911	CcSEcCtD
Auranofin—Stomatitis—Doxorubicin—prostate cancer	0.000211	0.000911	CcSEcCtD
Auranofin—Anorexia—Docetaxel—prostate cancer	0.000211	0.00091	CcSEcCtD
Auranofin—Abdominal pain—Etoposide—prostate cancer	0.000211	0.000908	CcSEcCtD
Auranofin—Conjunctivitis—Doxorubicin—prostate cancer	0.000211	0.000908	CcSEcCtD
Auranofin—Thrombocytopenia—Capecitabine—prostate cancer	0.00021	0.000905	CcSEcCtD
Auranofin—Haematuria—Doxorubicin—prostate cancer	0.000207	0.000891	CcSEcCtD
Auranofin—Anorexia—Capecitabine—prostate cancer	0.000205	0.000881	CcSEcCtD
Auranofin—Nausea—Estradiol—prostate cancer	0.000204	0.000881	CcSEcCtD
Auranofin—Vomiting—Mitoxantrone—prostate cancer	0.000204	0.000878	CcSEcCtD
Auranofin—Visual impairment—Epirubicin—prostate cancer	0.000203	0.000874	CcSEcCtD
Auranofin—Agranulocytosis—Doxorubicin—prostate cancer	0.000202	0.000872	CcSEcCtD
Auranofin—Rash—Mitoxantrone—prostate cancer	0.000202	0.000871	CcSEcCtD
Auranofin—Dermatitis—Mitoxantrone—prostate cancer	0.000202	0.00087	CcSEcCtD
Auranofin—Eye disorder—Epirubicin—prostate cancer	0.000197	0.000847	CcSEcCtD
Auranofin—Dyspepsia—Docetaxel—prostate cancer	0.000195	0.000841	CcSEcCtD
Auranofin—Decreased appetite—Docetaxel—prostate cancer	0.000193	0.00083	CcSEcCtD
Auranofin—Nausea—Mitoxantrone—prostate cancer	0.00019	0.000821	CcSEcCtD
Auranofin—Constipation—Docetaxel—prostate cancer	0.00019	0.000817	CcSEcCtD
Auranofin—Dyspepsia—Capecitabine—prostate cancer	0.000189	0.000814	CcSEcCtD
Auranofin—Pruritus—Etoposide—prostate cancer	0.000189	0.000813	CcSEcCtD
Auranofin—Visual impairment—Doxorubicin—prostate cancer	0.000188	0.000809	CcSEcCtD
Auranofin—Decreased appetite—Capecitabine—prostate cancer	0.000187	0.000804	CcSEcCtD
Auranofin—Alopecia—Epirubicin—prostate cancer	0.000186	0.000801	CcSEcCtD
Auranofin—Constipation—Capecitabine—prostate cancer	0.000184	0.000791	CcSEcCtD
Auranofin—Diarrhoea—Etoposide—prostate cancer	0.000182	0.000786	CcSEcCtD
Auranofin—Anorexia—Prednisone—prostate cancer	0.000182	0.000785	CcSEcCtD
Auranofin—Eye disorder—Doxorubicin—prostate cancer	0.000182	0.000784	CcSEcCtD
Auranofin—Gastrointestinal pain—Docetaxel—prostate cancer	0.000181	0.000781	CcSEcCtD
Auranofin—Flatulence—Epirubicin—prostate cancer	0.000181	0.000778	CcSEcCtD
Auranofin—Dysgeusia—Epirubicin—prostate cancer	0.000179	0.000773	CcSEcCtD
Auranofin—Gastrointestinal pain—Capecitabine—prostate cancer	0.000175	0.000756	CcSEcCtD
Auranofin—Abdominal pain—Docetaxel—prostate cancer	0.000175	0.000755	CcSEcCtD
Auranofin—Alopecia—Doxorubicin—prostate cancer	0.000172	0.000741	CcSEcCtD
Auranofin—Urticaria—Capecitabine—prostate cancer	0.00017	0.000735	CcSEcCtD
Auranofin—Abdominal pain—Capecitabine—prostate cancer	0.00017	0.000731	CcSEcCtD
Auranofin—Vomiting—Etoposide—prostate cancer	0.00017	0.000731	CcSEcCtD
Auranofin—Anaemia—Epirubicin—prostate cancer	0.000169	0.00073	CcSEcCtD
Auranofin—Dyspepsia—Prednisone—prostate cancer	0.000168	0.000725	CcSEcCtD
Auranofin—Rash—Etoposide—prostate cancer	0.000168	0.000725	CcSEcCtD
Auranofin—Dermatitis—Etoposide—prostate cancer	0.000168	0.000724	CcSEcCtD
Auranofin—Flatulence—Doxorubicin—prostate cancer	0.000167	0.00072	CcSEcCtD
Auranofin—Decreased appetite—Prednisone—prostate cancer	0.000166	0.000716	CcSEcCtD
Auranofin—Dysgeusia—Doxorubicin—prostate cancer	0.000166	0.000715	CcSEcCtD
Auranofin—Leukopenia—Epirubicin—prostate cancer	0.000164	0.000707	CcSEcCtD
Auranofin—Constipation—Prednisone—prostate cancer	0.000163	0.000704	CcSEcCtD
Auranofin—Nausea—Etoposide—prostate cancer	0.000158	0.000683	CcSEcCtD
Auranofin—Pruritus—Docetaxel—prostate cancer	0.000157	0.000676	CcSEcCtD
Auranofin—Anaemia—Doxorubicin—prostate cancer	0.000157	0.000675	CcSEcCtD
Auranofin—Gastrointestinal pain—Prednisone—prostate cancer	0.000156	0.000674	CcSEcCtD
Auranofin—Urticaria—Prednisone—prostate cancer	0.000152	0.000654	CcSEcCtD
Auranofin—Pruritus—Capecitabine—prostate cancer	0.000152	0.000654	CcSEcCtD
Auranofin—Leukopenia—Doxorubicin—prostate cancer	0.000152	0.000654	CcSEcCtD
Auranofin—Diarrhoea—Docetaxel—prostate cancer	0.000152	0.000653	CcSEcCtD
Auranofin—Abdominal pain—Prednisone—prostate cancer	0.000151	0.000651	CcSEcCtD
Auranofin—Diarrhoea—Capecitabine—prostate cancer	0.000147	0.000633	CcSEcCtD
Auranofin—Thrombocytopenia—Epirubicin—prostate cancer	0.000146	0.000631	CcSEcCtD
Auranofin—Anorexia—Epirubicin—prostate cancer	0.000143	0.000614	CcSEcCtD
Auranofin—Vomiting—Docetaxel—prostate cancer	0.000141	0.000607	CcSEcCtD
Auranofin—Rash—Docetaxel—prostate cancer	0.00014	0.000602	CcSEcCtD
Auranofin—Dermatitis—Docetaxel—prostate cancer	0.00014	0.000602	CcSEcCtD
Auranofin—Vomiting—Capecitabine—prostate cancer	0.000136	0.000588	CcSEcCtD
Auranofin—Thrombocytopenia—Doxorubicin—prostate cancer	0.000135	0.000584	CcSEcCtD
Auranofin—Rash—Capecitabine—prostate cancer	0.000135	0.000583	CcSEcCtD
Auranofin—Pruritus—Prednisone—prostate cancer	0.000135	0.000583	CcSEcCtD
Auranofin—Dermatitis—Capecitabine—prostate cancer	0.000135	0.000583	CcSEcCtD
Auranofin—Anorexia—Doxorubicin—prostate cancer	0.000132	0.000568	CcSEcCtD
Auranofin—Nausea—Docetaxel—prostate cancer	0.000132	0.000567	CcSEcCtD
Auranofin—Dyspepsia—Epirubicin—prostate cancer	0.000132	0.000567	CcSEcCtD
Auranofin—Diarrhoea—Prednisone—prostate cancer	0.000131	0.000564	CcSEcCtD
Auranofin—Decreased appetite—Epirubicin—prostate cancer	0.00013	0.00056	CcSEcCtD
Auranofin—Constipation—Epirubicin—prostate cancer	0.000128	0.000551	CcSEcCtD
Auranofin—Nausea—Capecitabine—prostate cancer	0.000127	0.000549	CcSEcCtD
Auranofin—Gastrointestinal pain—Epirubicin—prostate cancer	0.000122	0.000527	CcSEcCtD
Auranofin—Dyspepsia—Doxorubicin—prostate cancer	0.000122	0.000525	CcSEcCtD
Auranofin—Vomiting—Prednisone—prostate cancer	0.000122	0.000524	CcSEcCtD
Auranofin—Rash—Prednisone—prostate cancer	0.000121	0.000519	CcSEcCtD
Auranofin—Dermatitis—Prednisone—prostate cancer	0.00012	0.000519	CcSEcCtD
Auranofin—Decreased appetite—Doxorubicin—prostate cancer	0.00012	0.000518	CcSEcCtD
Auranofin—Urticaria—Epirubicin—prostate cancer	0.000119	0.000512	CcSEcCtD
Auranofin—Constipation—Doxorubicin—prostate cancer	0.000118	0.00051	CcSEcCtD
Auranofin—Abdominal pain—Epirubicin—prostate cancer	0.000118	0.000509	CcSEcCtD
Auranofin—Nausea—Prednisone—prostate cancer	0.000114	0.000489	CcSEcCtD
Auranofin—Gastrointestinal pain—Doxorubicin—prostate cancer	0.000113	0.000487	CcSEcCtD
Auranofin—Urticaria—Doxorubicin—prostate cancer	0.00011	0.000474	CcSEcCtD
Auranofin—Abdominal pain—Doxorubicin—prostate cancer	0.000109	0.000471	CcSEcCtD
Auranofin—Pruritus—Epirubicin—prostate cancer	0.000106	0.000456	CcSEcCtD
Auranofin—Diarrhoea—Epirubicin—prostate cancer	0.000102	0.000441	CcSEcCtD
Auranofin—Pruritus—Doxorubicin—prostate cancer	9.79e-05	0.000422	CcSEcCtD
Auranofin—Vomiting—Epirubicin—prostate cancer	9.51e-05	0.00041	CcSEcCtD
Auranofin—Diarrhoea—Doxorubicin—prostate cancer	9.46e-05	0.000408	CcSEcCtD
Auranofin—Rash—Epirubicin—prostate cancer	9.43e-05	0.000406	CcSEcCtD
Auranofin—Dermatitis—Epirubicin—prostate cancer	9.42e-05	0.000406	CcSEcCtD
Auranofin—Nausea—Epirubicin—prostate cancer	8.88e-05	0.000383	CcSEcCtD
Auranofin—Vomiting—Doxorubicin—prostate cancer	8.8e-05	0.000379	CcSEcCtD
Auranofin—Rash—Doxorubicin—prostate cancer	8.72e-05	0.000376	CcSEcCtD
Auranofin—Dermatitis—Doxorubicin—prostate cancer	8.71e-05	0.000375	CcSEcCtD
Auranofin—Nausea—Doxorubicin—prostate cancer	8.22e-05	0.000354	CcSEcCtD
Auranofin—ALB—Metabolism—UMPS—prostate cancer	2.18e-05	8.18e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling by NGF—PIK3CA—prostate cancer	2.17e-05	8.16e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—RXRA—prostate cancer	2.16e-05	8.14e-05	CbGpPWpGaD
Auranofin—ALB—Transmembrane transport of small molecules—NCOA1—prostate cancer	2.16e-05	8.13e-05	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—FGF2—prostate cancer	2.14e-05	8.05e-05	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—JAK2—prostate cancer	2.14e-05	8.04e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—LDHB—prostate cancer	2.13e-05	8.02e-05	CbGpPWpGaD
Auranofin—ALB—Platelet activation, signaling and aggregation—IL2—prostate cancer	2.12e-05	7.98e-05	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—BCL2—prostate cancer	2.12e-05	7.96e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—CYP3A5—prostate cancer	2.09e-05	7.87e-05	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—MDM2—prostate cancer	2.09e-05	7.84e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—IL18—prostate cancer	2.09e-05	7.84e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—PTHLH—prostate cancer	2.06e-05	7.75e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—TGFBR1—prostate cancer	2.06e-05	7.75e-05	CbGpPWpGaD
Auranofin—ALB—Transmembrane transport of small molecules—RXRA—prostate cancer	2.06e-05	7.74e-05	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—ERBB2—prostate cancer	2.06e-05	7.73e-05	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—PIK3CB—prostate cancer	2.03e-05	7.63e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—AKR1C3—prostate cancer	2.03e-05	7.63e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—PDHA1—prostate cancer	2.02e-05	7.6e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—TCN2—prostate cancer	2.02e-05	7.6e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—UCP3—prostate cancer	2.02e-05	7.6e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—GSTA3—prostate cancer	2.02e-05	7.6e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—PDGFRB—prostate cancer	2.02e-05	7.6e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—PRKACB—prostate cancer	2.02e-05	7.59e-05	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—MDM2—prostate cancer	2e-05	7.53e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—ITGB3—prostate cancer	1.99e-05	7.47e-05	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—ERBB2—prostate cancer	1.98e-05	7.43e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—PPP3CA—prostate cancer	1.97e-05	7.39e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—THBS1—prostate cancer	1.97e-05	7.39e-05	CbGpPWpGaD
Auranofin—IKBKB—Cytokine Signaling in Immune system—IL6—prostate cancer	1.95e-05	7.35e-05	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—PIK3CB—prostate cancer	1.95e-05	7.33e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—ANXA1—prostate cancer	1.94e-05	7.29e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—SLC22A3—prostate cancer	1.93e-05	7.25e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—HSD3B1—prostate cancer	1.93e-05	7.25e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling by NGF—IL6—prostate cancer	1.92e-05	7.22e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—ERBB3—prostate cancer	1.91e-05	7.18e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—FGFR2—prostate cancer	1.91e-05	7.17e-05	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—CDKN1B—prostate cancer	1.91e-05	7.16e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—PRKCZ—prostate cancer	1.9e-05	7.15e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—LPL—prostate cancer	1.87e-05	7.04e-05	CbGpPWpGaD
Auranofin—ALB—Platelet activation, signaling and aggregation—SRC—prostate cancer	1.85e-05	6.97e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—TBXAS1—prostate cancer	1.85e-05	6.95e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—GSTA4—prostate cancer	1.85e-05	6.95e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—FGFR4—prostate cancer	1.84e-05	6.91e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—PARP1—prostate cancer	1.84e-05	6.91e-05	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—CDKN1B—prostate cancer	1.83e-05	6.88e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—CALCA—prostate cancer	1.82e-05	6.82e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—CYP1A1—prostate cancer	1.81e-05	6.8e-05	CbGpPWpGaD
Auranofin—ALB—Platelet activation, signaling and aggregation—VEGFA—prostate cancer	1.8e-05	6.78e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—GSTA2—prostate cancer	1.8e-05	6.78e-05	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—CTNNB1—prostate cancer	1.8e-05	6.77e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—ABCG5—prostate cancer	1.78e-05	6.69e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—SULT1A1—prostate cancer	1.78e-05	6.69e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—CXCL12—prostate cancer	1.77e-05	6.67e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling by NGF—AKT1—prostate cancer	1.77e-05	6.66e-05	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—CDKN1A—prostate cancer	1.76e-05	6.61e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—BCL2L1—prostate cancer	1.76e-05	6.61e-05	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—PTEN—prostate cancer	1.75e-05	6.6e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—PLAU—prostate cancer	1.75e-05	6.57e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—GSTA1—prostate cancer	1.74e-05	6.54e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—HSD3B2—prostate cancer	1.72e-05	6.46e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—GSTO1—prostate cancer	1.72e-05	6.46e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—NAT2—prostate cancer	1.72e-05	6.46e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—CAV1—prostate cancer	1.71e-05	6.42e-05	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—CDKN1A—prostate cancer	1.69e-05	6.35e-05	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—PTEN—prostate cancer	1.68e-05	6.33e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—TLR4—prostate cancer	1.68e-05	6.3e-05	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—EP300—prostate cancer	1.67e-05	6.29e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—CASP9—prostate cancer	1.67e-05	6.28e-05	CbGpPWpGaD
Auranofin—ALB—Platelet activation, signaling and aggregation—TGFB1—prostate cancer	1.66e-05	6.23e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	1.65e-05	6.22e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—PLCB2—prostate cancer	1.65e-05	6.2e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—LRP2—prostate cancer	1.65e-05	6.2e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—CYP2C18—prostate cancer	1.65e-05	6.2e-05	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—SRC—prostate cancer	1.63e-05	6.12e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—NGFR—prostate cancer	1.62e-05	6.08e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—PRKCQ—prostate cancer	1.62e-05	6.08e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—P4HB—prostate cancer	1.62e-05	6.08e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—ICAM1—prostate cancer	1.61e-05	6.04e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—MAP3K7—prostate cancer	1.6e-05	6.01e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—BAD—prostate cancer	1.59e-05	5.99e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—SLC22A1—prostate cancer	1.57e-05	5.91e-05	CbGpPWpGaD
Auranofin—ALB—Transmembrane transport of small molecules—PPARA—prostate cancer	1.57e-05	5.91e-05	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—SRC—prostate cancer	1.56e-05	5.87e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—PIK3CG—prostate cancer	1.56e-05	5.85e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	1.55e-05	5.84e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—EGF—prostate cancer	1.54e-05	5.78e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—FGF10—prostate cancer	1.54e-05	5.78e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—SULT2A1—prostate cancer	1.53e-05	5.76e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—IRS1—prostate cancer	1.53e-05	5.73e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—EGF—prostate cancer	1.53e-05	5.73e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—ADRB2—prostate cancer	1.52e-05	5.72e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—MED12—prostate cancer	1.51e-05	5.67e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—GNG5—prostate cancer	1.5e-05	5.62e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—VAV3—prostate cancer	1.48e-05	5.58e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—GSK3B—prostate cancer	1.48e-05	5.57e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—TGFBR2—prostate cancer	1.46e-05	5.5e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—CREBBP—prostate cancer	1.44e-05	5.42e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—NCOA3—prostate cancer	1.44e-05	5.42e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—ITPR1—prostate cancer	1.44e-05	5.41e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—CREBBP—prostate cancer	1.43e-05	5.38e-05	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—EGFR—prostate cancer	1.43e-05	5.36e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—IGF1—prostate cancer	1.42e-05	5.35e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—CDH1—prostate cancer	1.42e-05	5.34e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	1.42e-05	5.32e-05	CbGpPWpGaD
Auranofin—ALB—Platelet activation, signaling and aggregation—PIK3CA—prostate cancer	1.41e-05	5.3e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—IGF1R—prostate cancer	1.38e-05	5.17e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—HPGDS—prostate cancer	1.37e-05	5.17e-05	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—EGFR—prostate cancer	1.37e-05	5.15e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—PIK3CD—prostate cancer	1.37e-05	5.14e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—CYP2C19—prostate cancer	1.37e-05	5.14e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—MAP2K1—prostate cancer	1.37e-05	5.13e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—PIK3CD—prostate cancer	1.36e-05	5.1e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—SERPINE1—prostate cancer	1.35e-05	5.08e-05	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—KRAS—prostate cancer	1.35e-05	5.06e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—GSTT1—prostate cancer	1.33e-05	5.01e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—ACHE—prostate cancer	1.33e-05	5.01e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—LPL—prostate cancer	1.32e-05	4.96e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—CYP2A6—prostate cancer	1.32e-05	4.95e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	1.31e-05	4.94e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—PDGFRB—prostate cancer	1.31e-05	4.91e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—FGF2—prostate cancer	1.3e-05	4.88e-05	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—KRAS—prostate cancer	1.29e-05	4.86e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—NOS3—prostate cancer	1.29e-05	4.85e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—AKR1C3—prostate cancer	1.28e-05	4.82e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—PRKACB—prostate cancer	1.28e-05	4.79e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—ITGB3—prostate cancer	1.27e-05	4.79e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—CYP17A1—prostate cancer	1.26e-05	4.74e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—JAK2—prostate cancer	1.25e-05	4.72e-05	CbGpPWpGaD
Auranofin—ALB—Transmembrane transport of small molecules—CREBBP—prostate cancer	1.25e-05	4.69e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—JAK2—prostate cancer	1.24e-05	4.68e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	1.24e-05	4.68e-05	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—PIK3CA—prostate cancer	1.24e-05	4.65e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—ERBB3—prostate cancer	1.24e-05	4.64e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—FGFR2—prostate cancer	1.23e-05	4.64e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—BCL2—prostate cancer	1.23e-05	4.64e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—MDM2—prostate cancer	1.22e-05	4.57e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—NCOA2—prostate cancer	1.2e-05	4.52e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—ERBB2—prostate cancer	1.2e-05	4.5e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—PIK3CB—prostate cancer	1.19e-05	4.48e-05	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—PIK3CA—prostate cancer	1.19e-05	4.47e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—TERT—prostate cancer	1.18e-05	4.45e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—PIK3CB—prostate cancer	1.18e-05	4.45e-05	CbGpPWpGaD
Auranofin—ALB—Platelet activation, signaling and aggregation—AKT1—prostate cancer	1.15e-05	4.33e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—SLC5A5—prostate cancer	1.15e-05	4.31e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—HIF1A—prostate cancer	1.13e-05	4.26e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—CYP2E1—prostate cancer	1.12e-05	4.21e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—CDKN1B—prostate cancer	1.11e-05	4.17e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—NQO1—prostate cancer	1.11e-05	4.17e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—LEP—prostate cancer	1.11e-05	4.16e-05	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—IL6—prostate cancer	1.1e-05	4.12e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—CAV1—prostate cancer	1.1e-05	4.12e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—IL2—prostate cancer	1.09e-05	4.11e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—TH—prostate cancer	1.09e-05	4.11e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—IL2—prostate cancer	1.09e-05	4.08e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	1.08e-05	4.08e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—KDR—prostate cancer	1.08e-05	4.07e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—CYP3A4—prostate cancer	1.08e-05	4.06e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	1.08e-05	4.04e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—CYP1B1—prostate cancer	1.06e-05	3.99e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—ESR1—prostate cancer	1.06e-05	3.97e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—CTNNB1—prostate cancer	1.05e-05	3.94e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—BAD—prostate cancer	1.03e-05	3.87e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—GGT1—prostate cancer	1.03e-05	3.87e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—CDKN1A—prostate cancer	1.02e-05	3.85e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—PTEN—prostate cancer	1.02e-05	3.84e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—NCOA1—prostate cancer	1.01e-05	3.81e-05	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—AKT1—prostate cancer	1.01e-05	3.8e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—CYP19A1—prostate cancer	9.99e-06	3.76e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—APC—prostate cancer	9.98e-06	3.75e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—PIK3CG—prostate cancer	9.98e-06	3.75e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—EGF—prostate cancer	9.86e-06	3.71e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—IRS1—prostate cancer	9.86e-06	3.71e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—EP300—prostate cancer	9.82e-06	3.69e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—EP300—prostate cancer	9.74e-06	3.66e-05	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—AKT1—prostate cancer	9.71e-06	3.65e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—RXRA—prostate cancer	9.64e-06	3.62e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—GSK3B—prostate cancer	9.57e-06	3.6e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—SRC—prostate cancer	9.55e-06	3.59e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—SRC—prostate cancer	9.48e-06	3.56e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—INS—prostate cancer	9.44e-06	3.55e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	9.38e-06	3.52e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—VEGFA—prostate cancer	9.3e-06	3.5e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—COMT—prostate cancer	9.29e-06	3.49e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—CREBBP—prostate cancer	9.25e-06	3.48e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—GSTP1—prostate cancer	9.24e-06	3.47e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—STAT3—prostate cancer	9.14e-06	3.44e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—IGF1—prostate cancer	9.13e-06	3.43e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—ITPR1—prostate cancer	9.09e-06	3.42e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—EP300—prostate cancer	8.94e-06	3.36e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—MAP2K1—prostate cancer	8.83e-06	3.32e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—PIK3CD—prostate cancer	8.77e-06	3.3e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—SERPINE1—prostate cancer	8.67e-06	3.26e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—TYMS—prostate cancer	8.59e-06	3.23e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—TGFB1—prostate cancer	8.54e-06	3.21e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—GSTM1—prostate cancer	8.49e-06	3.19e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—FGF2—prostate cancer	8.4e-06	3.16e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—LPL—prostate cancer	8.34e-06	3.13e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—EGFR—prostate cancer	8.3e-06	3.12e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—NOS3—prostate cancer	8.28e-06	3.11e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—CYP1A1—prostate cancer	8.05e-06	3.03e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—JAK2—prostate cancer	8.05e-06	3.03e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—ERCC2—prostate cancer	7.98e-06	3e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—KRAS—prostate cancer	7.91e-06	2.97e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—MDM2—prostate cancer	7.86e-06	2.95e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—KRAS—prostate cancer	7.85e-06	2.95e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—ERBB2—prostate cancer	7.75e-06	2.91e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—PIK3CB—prostate cancer	7.64e-06	2.87e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—MTHFR—prostate cancer	7.51e-06	2.82e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—PPARA—prostate cancer	7.36e-06	2.77e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—CXCL8—prostate cancer	7.35e-06	2.76e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—PIK3CA—prostate cancer	7.26e-06	2.73e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—PIK3CA—prostate cancer	7.21e-06	2.71e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—CDKN1B—prostate cancer	7.17e-06	2.7e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—CASP3—prostate cancer	7.03e-06	2.64e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—TP53—prostate cancer	7.03e-06	2.64e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—IL2—prostate cancer	7.02e-06	2.64e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—CAV1—prostate cancer	6.92e-06	2.6e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—CCND1—prostate cancer	6.84e-06	2.57e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—CTNNB1—prostate cancer	6.78e-06	2.55e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—MMP9—prostate cancer	6.64e-06	2.5e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—CDKN1A—prostate cancer	6.62e-06	2.49e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	6.61e-06	2.49e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—PTEN—prostate cancer	6.61e-06	2.48e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—IL6—prostate cancer	6.38e-06	2.4e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—PIK3CG—prostate cancer	6.31e-06	2.37e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—EP300—prostate cancer	6.3e-06	2.37e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—SRC—prostate cancer	6.13e-06	2.3e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—INS—prostate cancer	5.97e-06	2.24e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—VEGFA—prostate cancer	5.97e-06	2.24e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—AKT1—prostate cancer	5.93e-06	2.23e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—STAT3—prostate cancer	5.91e-06	2.22e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—AKT1—prostate cancer	5.89e-06	2.21e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—CREBBP—prostate cancer	5.85e-06	2.2e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—PIK3CD—prostate cancer	5.54e-06	2.08e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—MYC—prostate cancer	5.49e-06	2.06e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—TGFB1—prostate cancer	5.48e-06	2.06e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—EGFR—prostate cancer	5.37e-06	2.02e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—NOS3—prostate cancer	5.23e-06	1.97e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—KRAS—prostate cancer	5.07e-06	1.91e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—PIK3CB—prostate cancer	4.83e-06	1.82e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—PTGS2—prostate cancer	4.79e-06	1.8e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—PIK3CA—prostate cancer	4.66e-06	1.75e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—TP53—prostate cancer	4.51e-06	1.69e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—PTEN—prostate cancer	4.18e-06	1.57e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—IL6—prostate cancer	4.13e-06	1.55e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—EP300—prostate cancer	3.98e-06	1.5e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—AKT1—prostate cancer	3.81e-06	1.43e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—PIK3CA—prostate cancer	2.95e-06	1.11e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—AKT1—prostate cancer	2.41e-06	9.05e-06	CbGpPWpGaD
